Literature DB >> 2536136

Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.

K S Erlich1, J Mills, P Chatis, G J Mertz, D F Busch, S E Follansbee, R M Grant, C S Crumpacker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2536136     DOI： 10.1056/NEJM198902023200506

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  78 in total

Review 1.  Molecular diagnosis of herpes simplex virus infections in the central nervous system.

Authors:  Y W Tang; P S Mitchell; M J Espy; T F Smith; D H Persing
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

Review 2.  Infectious disease therapy in the 1990s. Where are we heading?

Authors:  M Rozenberg-Arska; M R Visser
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 3.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 4.  Clinical management of the complications of HIV infection.

Authors:  T G Cooney
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

5.  Clinical evaluation of carbocyclic oxetanocin G eyedrops in the treatment of herpes simplex corneal ulcers.

Authors:  H Shiota; K Nitta; T Naito; Y Mimura; T Maruyama
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

6.  [Efficacy and tolerability of topical foscarnet sodium in treatment of herpes labialis. Results of post-marketing surveillance].

Authors:  G Gross; D Braun
Journal:  Hautarzt       Date:  2006-01       Impact factor: 0.751

7.  Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex.

Authors:  D H Katz; J F Marcelletti; M H Khalil; L E Pope; L R Katz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 8.  Prophylaxis for genital herpes. Should it be used routinely?

Authors:  A Mindel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

9.  Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.

Authors:  R Chambers; G Y Gillespie; L Soroceanu; S Andreansky; S Chatterjee; J Chou; B Roizman; R J Whitley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.

Authors:  Mark N Prichard; Debra C Quenelle; Caroll B Hartline; Emma A Harden; Geraldine Jefferson; Samuel L Frederick; Shannon L Daily; Richard J Whitley; Kamal N Tiwari; Joseph A Maddry; John A Secrist; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.